Novartis in-licenses ImmunoGen's armed-antibody tech; Alexion releases new Soliris data;

@FierceBiotech: Shire pays a steep premium to nab ViroPharma in $4.2B deal. More | Follow @FierceBiotech

@JohnCFierce: Just a few weeks ago Zalicus ($ZLCS) did a 6 for one reverse split to get its stock price back into compliance. Oh well. | Follow @JohnCFierce

@DamianFierce: Still-blazing IPO market takes Ultragenyx from "next year" to "right now." News | Follow @DamianFierce

@EmilyMFierce: Japanese Global Health Innovative Technology Fund awards $5.7M in grants for infectious disease vaccine work. Story | Follow @EmilyMFierce

> Novartis ($NVS) has in-licensed ImmunoGen's antibody-drug conjugate technology for its oncology group. Release

> Alexion Pharmaceuticals ($ALXN) presented data from four clinical trials demonstrating the benefit of using Soliris to treat atypical hemolytic uremic syndrome, an ultra-rare disease associated with organ failure and premature death. Release

> Texas-based ZS Pharma, which last year raised a $46 million venture round, says that ZS-003 met its primary endpoint in a Phase III study for hyperkalemia. Release

Medical Device News

@FierceMedDev: Pfizer, marketing partner pay MA fine for ad overstating EpiPen's benefits. More | Follow @FierceMedDev

@MarkHFierce: Novartis is unloading its blood transfusion Dx unit for more than $1.6B PR. Article | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Chinese investors pursue groundbreaking med tech from Canada's MDI. Story | Follow @MichaelGFierce

> Topera rolls out next-gen heart imaging tech in wake of U.S., EU sign-offs. Story

> TB Dx maker Oxford Immunotec prices IPO shares. More

> FDA report: Intuitive's robots beneficial, but training still lacking. News

Pharma News

@FiercePharma:  Best-read special report this weekend: Top 10 Patent Losses for 2014. Report | Follow @FiercePharma

@CarlyHFierce:  Rare-disease co. ViroPharma finally snatched up after lots of speculation--Shire gets it for $4.2B. Release | Follow @CarlyHFierce

> FDA slaps Aegerion for CEO's fast-and-loose interviews with CNBC. Story

> AstraZeneca to build £120 million U.K. plant. News

> Novartis hives off blood diagnostics for $1.7B in first slim-down sale. Article

CRO News

> Cel-Sci demands $50M from inVentiv over alleged trial fraud. More

> Quintiles paid $146.5M for Novella. Article

> Capsugel bets $20M on Bend's commercial manufacturing. Story

> AMRI steers clear of FDA warning letter after years of fixes. Piece

> Covance partners up for biologics safety testing. Story

Biotech IT News

> Scientists increasingly receptive to life science vendors on social media. News

> Open-access genomics database causes hand-wringing in U.K. More

> Catalent creates web-based tool to ease drug delivery tech selection. Story

> BioDatomics pitches open-source, freemium bioinformatics package. Piece

> Advocacy groups crowdsourcing patient views on risk-benefit of drugs. News